Notícias e Atividades da Crown Bioscience

A Crown Bioscience pertence à JSR.

JSR é uma empresa listada sob o símbolo 4185 (JP).

JSR tem presença direta em 3 países.

JSR possui 5 subsidiárias incluindo Crown Bioscience, Indivumed Services e Inpria.

Eles estão dentro:

• Biotecnologia67%
• Produtos Químicos17%
• Outro17%

Veja o organograma con seus 25 executivos principais

Biografias mais buscadas da Crown Bioscience

• John Gu, Chief Executive Officer and Chief Operations officer
• Alex Slater, Chief Business Officer
• Maria Radino, Vice President, Global Quality and Regulatory Compli...

Recentes movimentos de executivos em Crown Bioscience

• Donald Beqollari, Senior Director, Global Clinical Network, deixou a Companhia  (Notícia publicada em 19 de junho de 2026).

Criar um alerta
para seguir os movimentos de executivos da Crown Bioscience.

JSR possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Crown Bioscience

• Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development
• https://www.crownbio.com/ja-jp/about-us/news-and-events
• https://www.crownbio.com/zh-cn/about-us/news-and-events
• Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology
• AACR 2026: Crown Bioscience Showcases Integrated Platforms Enabling Next-Generation Oncology Modalities, Including ADCs and Radiopharmaceuticals
• Next-Generation Biologics in Oncology - March 11, 2026 - London UK
• Crown Bioscience CEO John Gu Named to The Healthcare Technology Report’s Top CEOs of 2025
• Crown Bioscience News & Events (31)
• https://blog.crownbio.com/ja-jp/about-us/news-and-events
• https://blog.crownbio.com/zh-cn/about-us/news-and-events
• View more press releases Close

Redes sociais sobre Crown Bioscience

• Crown Bioscience na Wikipedia, Google News e Yahoo Finance
• Crown Bioscience na LinkedIn, X (Twitter) e YouTube